Detalhe da pesquisa
1.
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature
; 566(7745): E13, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30733620
2.
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature
; 565(7738): 240-245, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30568303
3.
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(11): 1599-1611, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27720136
4.
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Cancer Immunol Res
; 11(7): 925-945, 2023 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37172100
5.
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Clin Cancer Res
; 28(12): 2555-2566, 2022 06 13.
Artigo
Inglês
| MEDLINE | ID: mdl-35421231
6.
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Nat Med
; 18(8): 1254-61, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22842478